Migraine pain relief in as little as 10 minutes
Some patients experience migraine pain relief in as little as 10 minutes with just one spray (13% vs. 5% for placebo).*1-3
Efficacy of Tosymra is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.
*Time to onset and degree of pain relief varies by patient.Learn More
Tosymra for free†
Commercially insured patients pay $0† per prescription, regardless of coverage, only through our pharmacy partner, Blink Pharmacy Plus.
†Restrictions and quantity limits apply. Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.